These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31398271)

  • 1. Targeting CDK9 for treatment of colorectal cancer.
    Rahaman MH; Lam F; Zhong L; Teo T; Adams J; Yu M; Milne RW; Pepper C; Lokman NA; Ricciardelli C; Oehler MK; Wang S
    Mol Oncol; 2019 Oct; 13(10):2178-2193. PubMed ID: 31398271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
    Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
    Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.
    Lam F; Abbas AY; Shao H; Teo T; Adams J; Li P; Bradshaw TD; Fischer PM; Walsby E; Pepper C; Chen Y; Ding J; Wang S
    Oncotarget; 2014 Sep; 5(17):7691-704. PubMed ID: 25277198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
    Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
    Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
    Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
    Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.
    Liu X; Lam F; Shi S; Fischer PM; Wang S
    Invest New Drugs; 2012 Jun; 30(3):889-97. PubMed ID: 21331744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
    Liu X; Shi S; Lam F; Pepper C; Fischer PM; Wang S
    Int J Cancer; 2012 Mar; 130(5):1216-26. PubMed ID: 21484792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
    Walsby E; Pratt G; Shao H; Abbas AY; Fischer PM; Bradshaw TD; Brennan P; Fegan C; Wang S; Pepper C
    Oncotarget; 2014 Jan; 5(2):375-85. PubMed ID: 24495868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Yang L; Zhou F; Zhuang Y; Liu Y; Xu L; Zhao H; Xiang Y; Dai X; Liu Z; Huang X; Wang L; Zhao C
    Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
    Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
    Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy.
    Zhang Z; Gao W; Zhou L; Chen Y; Qin S; Zhang L; Liu J; He Y; Lei Y; Chen HN; Han J; Zhou ZG; Nice EC; Li C; Huang C; Wei X
    Theranostics; 2019; 9(17):4878-4892. PubMed ID: 31410188
    [No Abstract]   [Full Text] [Related]  

  • 12. CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Rahman R; Rahaman MH; Hanson AR; Choo N; Xie J; Townley SL; Shrestha R; Hassankhani R; Islam S; Ramm S; Simpson KJ; Risbridger GP; Best G; Centenera MM; Balk SP; Kichenadasse G; Taylor RA; Butler LM; Tilley WD; Conn SJ; Lawrence MG; Wang S; Selth LA
    Br J Cancer; 2024 Oct; 131(6):1092-1105. PubMed ID: 39117800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
    Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
    Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wang WJ; Gao L; Wang S; Huang W; Meng XY; Hu H; Chen Z; Sun J; Yuan Y; Zhou Y; Diao X; Huang R; Li J; Chen XH
    J Med Chem; 2024 Jun; 67(12):10035-10056. PubMed ID: 38885173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.
    Singh U; Chashoo G; Khan SU; Mahajan P; Nargotra A; Mahajan G; Singh A; Sharma A; Mintoo MJ; Guru SK; Aruri H; Thatikonda T; Sahu P; Chibber P; Kumar V; Mir SA; Bharate SS; Madishetti S; Nandi U; Singh G; Mondhe DM; Bhushan S; Malik F; Mignani S; Vishwakarma RA; Singh PP
    J Med Chem; 2017 Dec; 60(23):9470-9489. PubMed ID: 29144137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
    Alsfouk A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
    Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.